{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:31:25Z","timestamp":1761823885819,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T00:00:00Z","timestamp":1495065600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s10557-017-6728-z","type":"journal-article","created":{"date-parts":[[2017,5,17]],"date-time":"2017-05-17T21:44:07Z","timestamp":1495057447000},"page":"295-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect"],"prefix":"10.1007","volume":"31","author":[{"given":"Patr\u00edcia O.","family":"Guimar\u00e3es","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel M.","family":"Wojdyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azmil H.","family":"Abdul-Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg C.","family":"Flaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kennedy R.","family":"Lees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,5,18]]},"reference":[{"key":"6728_CR1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367.","journal-title":"Ann Intern Med"},{"key":"6728_CR2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.CIR.98.10.946","volume":"98","author":"EJ Benjamin","year":"1998","unstructured":"Benjamin EJ, Wolf PA, D\u2019Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham heart study. Circulation. 1998;98:946\u201352.","journal-title":"Circulation"},{"key":"6728_CR3","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/jama.2011.659","volume":"305","author":"D Conen","year":"2011","unstructured":"Conen D, Chae CU, Glynn RJ, et al. Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation. JAMA. 2011;305:2080\u20137.","journal-title":"JAMA"},{"key":"6728_CR4","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"6728_CR5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"6728_CR6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"6728_CR7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"6728_CR8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"6728_CR9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med"},{"key":"6728_CR10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","volume":"50","author":"HC Bucher","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50:683\u201391.","journal-title":"J Clin Epidemiol"},{"key":"6728_CR11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1067\/mhj.2001.111262","volume":"141","author":"LD Fisher","year":"2001","unstructured":"Fisher LD, Gent M, Buller HR. Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J. 2001;141:26\u201332.","journal-title":"Am Heart J"},{"key":"6728_CR12","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/eurheartj\/ehu455","volume":"36","author":"J McMurray","year":"2015","unstructured":"McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of lcz696 on clinical outcomes in heart failure. Eur Heart J. 2015;36:434\u20139.","journal-title":"Eur Heart J"},{"key":"6728_CR13","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/sim.1454","volume":"22","author":"S Durrleman","year":"2003","unstructured":"Durrleman S, Chaikin P. The use of putative placebo in active control trials: two applications in a regulatory setting. Stat Med. 2003;22:941\u201352.","journal-title":"Stat Med"},{"key":"6728_CR14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0197-2456(01)00155-6","volume":"23","author":"SJ Wang","year":"2002","unstructured":"Wang SJ, Hung HM, Tsong Y. Utility and pitfalls of some statistical methods in active controlled clinical trials. Control Clin Trials. 2002;23:15\u201328.","journal-title":"Control Clin Trials"},{"key":"6728_CR15","doi-asserted-by":"crossref","unstructured":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71\u201386.","DOI":"10.1136\/bmj.324.7329.71"},{"key":"6728_CR16","doi-asserted-by":"crossref","first-page":"e002197","DOI":"10.1161\/JAHA.115.002197","volume":"5","author":"SD Pokorney","year":"2016","unstructured":"Pokorney SD, Piccini JP, Stevens SR, et al. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: data from ROCKET AF. J Am Heart Assoc. 2016;5:e002197.","journal-title":"J Am Heart Assoc"},{"key":"6728_CR17","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1161\/01.CIR.0000118472.77237.FA","volume":"109","author":"JS Steinberg","year":"2004","unstructured":"Steinberg JS, Sadaniantz A, Kron J, et al. Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation. 2004;109:1973\u201380.","journal-title":"Circulation"},{"key":"6728_CR18","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","volume":"128","author":"E Marijon","year":"2013","unstructured":"Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128:2192\u2013201.","journal-title":"Circulation"},{"key":"6728_CR19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1161\/STROKEAHA.113.004506","volume":"45","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor xa inhibition compared with vitamin k antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke. 2014;45:1304\u201312.","journal-title":"Stroke"},{"key":"6728_CR20","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1161\/STROKEAHA.112.650614","volume":"43","author":"RG Hart","year":"2012","unstructured":"Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43:1511\u20137.","journal-title":"Stroke"},{"key":"6728_CR21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00415-011-6153-3","volume":"259","author":"A Cervera","year":"2012","unstructured":"Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol. 2012;259:212\u201324.","journal-title":"J Neurol"},{"key":"6728_CR22","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/eurheartj\/eht483","volume":"35","author":"JP Piccini","year":"2014","unstructured":"Piccini JP, Hammill BG, Sinner MF, et al. Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. Eur Heart J. 2014;35:250\u20136.","journal-title":"Eur Heart J"},{"key":"6728_CR23","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1093\/eurheartj\/ehp486","volume":"31","author":"DA Lane","year":"2010","unstructured":"Lane DA, Lip GY. Atrial fibrillation and mortality: the impact of antithrombotic therapy. Eur Heart J. 2010;31:2075\u20136.","journal-title":"Eur Heart J"},{"key":"6728_CR24","doi-asserted-by":"crossref","unstructured":"Lopes RD, Guimar\u00e3es PO, Kolls BJ, Wojdyla DM, Bushnell CD, Hanna M, et al. Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. Blood. 2017; in press.","DOI":"10.1182\/blood-2016-08-731638"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-017-6728-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-017-6728-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,9]],"date-time":"2017-08-09T00:35:01Z","timestamp":1502238901000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-017-6728-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,18]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["6728"],"URL":"https:\/\/doi.org\/10.1007\/s10557-017-6728-z","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2017,5,18]]}}}